Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Naturally occurring T cell mutations enhance engineered T cell therapies

Nature(2024)10.1038/s41586-024-07018-7Source: DataRank Database

Naturally occurring T cell mutations enhance engineered T cell therapies is a research paper published in Nature (2024). On theSindex it has a DataRank of 3.0. It has been cited 88 times, with 87 citing works in its 1-hop citation network.

N/A

3.0DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access88 citations · 87 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

BioProjectPRJNA1029944

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)Impact (FWCI 15.70)OA: greenTopics (66)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 23%Citation Network 77%

Base Score Contribution

0.673

From this paper's citation signal

Citation Network Contribution

2.3

From 67 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 87 citers.

Turbocharged CAR-T cells melt tumours in mice — using a trick from cancer cells
Nature20241 citations1 referencesContributes 0.693
Unveiling a novel fusion gene enhances CAR T cell therapy for solid tumors
Molecular Cancer20246 citations7 referencesContributes 0.278
Engineered CARD11–PIK3R3 T‐cell therapies as weapons of cancer mass destruction
MedComm20241 citations5 referencesContributes 0.139
Emerging T-cell lymphomas after CAR T-cell therapy
Leukemia202520 citations25 referencesContributes 0.122
Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in patients with T- and/or NK-cell lymphoma
Blood Advances202410 citations35 referencesContributes 0.069

Authors (15)

Jay Daniels ORCID,Yujin Lee ORCID,Iowis Zhu ORCID,Kathleen Cheng ORCID,Qing Liu ORCID

Live enrichment

PubMed:38326614 OpenAlex:https://openalex.org/W4391617619

National Institutes of Health

Grant: 5F31CA260790-02

Engineering Hybrid SynNotch CAR Receptors to Enhance Cell Therapies for Cancer

National Institutes of Health

Grant: 1DP2AI136599-01

Identifying Mechanisms Governing T Cell Diversity

National Institutes of Health

Grant: 3U54CA244438-01S5

UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer

National Institutes of Health

Grant: 5T32CA009560-39

Carcinogenesis Training Program

National Institutes of Health

Grant: 1DP2CA239143-01

Engineering the Next-generation of Custom Immune Cell Therapies

National Institutes of Health

Grant: 1F30CA265107-01

Dissecting mechanisms by which PD1 deletions drive aggressive cutaneous T cell lymphoma

NCI NIH HHS

Grant: R01 CA260064

NCI NIH HHS

Grant: F30 CA265107

NIAID NIH HHS

Grant: T32 AI007334

NIAID NIH HHS

Grant: DP2 AI136599

NCI NIH HHS

Grant: U54 CA244438

NCI NIH HHS

Grant: F31 CA260790

NIAMS NIH HHS

Grant: T32 AR060710

NCI NIH HHS

Grant: DP2 CA239143

NCI NIH HHS

Grant: K08 CA191019

NCI NIH HHS

Grant: T32 CA009560

FWCI

15.70

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

greenLicense: Springer Nature TDM

repositoryhttps://escholarship.org/content/qt69f633nx/qt69f633nx.pdf

publisherhttps://www.nature.com/articles/s41586-024-07018-7.pdf

publisherhttps://www.nature.com/articles/s41586-024-07018-7

repositoryhttps://escholarship.org/uc/item/69f633nx

Fields of Study

CAR-T cell therapy researchViral Infectious Diseases and Gene Expression in InsectsVirus-based gene therapy research03 medical and health sciences0302 clinical medicineHumansCARD Signaling Adaptor ProteinsCD4-Positive T-LymphocytesCytokinesEvolution, MolecularGuanylate CyclaseImmunotherapy, AdoptiveLymphoma, T-Cell, CutaneousMutationPhosphatidylinositol 3-KinasesSignal TransductionT-LymphocytesB-Cell CLL-Lymphoma 10 ProteinMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein

MeSH Terms

B-Cell CLL-Lymphoma 10 ProteinMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinGuanylate CyclaseHumansMutationNeoplasmsT-LymphocytesSignal TransductionCD4-Positive T-LymphocytesCytokinesImmunotherapy, AdoptiveLymphoma, T-Cell, CutaneousEvolution, MolecularPhosphatidylinositol 3-KinasesCARD Signaling Adaptor Proteins

Keywords

Chimeric antigen receptorT cellCancer researchCellImmunotherapyBiologyT-cell receptorComputational biologyImmunologyImmune systemGeneticsCD4-Positive T-LymphocytesLymphomaEvolutionT-LymphocytesAdoptive610MolecularT-CellB-Cell CLL-Lymphoma 10 ProteinImmunotherapy, AdoptiveLymphoma, T-Cell, CutaneousCARD Signaling Adaptor ProteinsEvolution, MolecularPhosphatidylinositol 3-KinasesCutaneousGuanylate CyclaseMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinMutationHumansCytokinesSignal Transduction

Sustainable Development Goals

SDG 0: No poverty